Vanda Pharmaceuticals’ stock tumbles after $220M loss

robot
Abstract generation in progress

Vanda Pharmaceuticals’ stock dropped significantly following a report of a $220 million loss. Additionally, the D.C. biotech company filed a shelf registration statement for $200 million, indicating plans to raise capital in the coming years. This financial news has led to investor concern, as reflected in the stock’s tumble.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)